CDK6 and glioma: SUMO1 is upregulated in glioma cells and tissues, and the SUMO1 modification of the cell cycle regulator CDK6 could upregulate its expression by stabilizing it and, thus, could promote cell malignant progression (Bellail et al. 2014).